Project Grant HT94252410650
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
The federal Project Grant award of $1,715,075.00 was provided by the Defense Health Agency to Beth Israel Deaconess Medical Center, Inc. (Bidmc) under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research on "The Role of TBI Derived DAMPS in Bacterial Pneumonia" over a period from September 30, 2023 to September 29, 2026. As a major academic medical center and teaching hospital, Bidmc has an extensive portfolio of federal grants and...
The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...
The Beth Israel Deaconess Medical Center, Inc. (doing business as Bidmc) received a $1,735,624 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from July 1, 2021 to June 30, 2025 to develop a strain-programmable bioadhesive patch to accelerate healing of diabetic ulcers. The Military Medical Research and Development program aims to transform military and public health through innovative...
This federal Project Grant award of $1,991,326.00, awarded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) aimed at suppressing barrier antimicrobial defenses in the context of trauma. The 3-year grant, with a performance period from September 30, 2024 to September 29, 2027, will enable Bidmc, a prominent academic medical center in...
This federal Project Grant award of $518,700.00 was made by the Defense Health Agency on July 1, 2024 to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, MA. The award is part of the Military Medical Research and Development (CFDA 12.420) program, which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the broader public. The funding will support Bidmc's project titled "EXPLOITING DISRUPTION IN TRANSCRIPTIONAL...
This Project Grant award of $1,723,552.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (BIDMC) to target specific long non-coding RNAs (lncRNAs) in novel combined therapies. The goal is to modulate the TSP1-dependent immune microenvironment vulnerabilities in advanced thyroid cancer. The research, spanning from September 1, 2025 to August 31, 2028, aims to...
This $345,800 Project Grant was awarded on May 1, 2024 by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The grant supports research on the "Role of Stress Granules in the Pathogenesis and Therapy of Pulmonary Hypertension", with a performance period from May 1, 2024 to April 30, 2026. The Military Medical Research and Development program funds a...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
The University of Massachusetts Medical School was awarded a $836,992 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on August 1, 2025, will fund research to investigate the effects of military-associated environmental toxins on motor neurons and glial cells in sporadic amyotrophic lateral sclerosis (ALS). The research aims to transform healthcare for military service members, veterans, and the broader...